Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI model may forecast prostate cancer recurrence after surgery

NCT ID NCT07682584

Knowledge-focused Sponsor: First Affiliated Hospital of Fujian Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study looks at men with localized prostate cancer who had robot-assisted surgery to remove the prostate. The goal is to find which factors—like PSA levels, tumor grade, or MRI results—best predict whether the cancer will come back (called biochemical recurrence). Researchers will use patient records and machine learning to build a risk-prediction tool. If accurate, it could help doctors decide who needs closer monitoring or extra treatment after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a predictive model that helps doctors personalize follow-up and treatment decisions after prostate cancer surgery.
What could go wrong
This is a retrospective analysis, so it can show associations but not prove cause and effect. The model needs validation in other groups before it can be used widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients with localized prostate adenocarcinoma (clinical stage T1-T2, N0M0) who underwent robot-assisted radical prostatectomy (RARP) at Fujian Medical University Affiliated First Hospital between January 2020 and May 2026. Consecutive patients meeting eligibility criteria are included. No specific sampling frame or probability sampling method is applied.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pathologically confirmed prostate adenocarcinoma Clinical stage localized prostate cancer (T1-T2, N0M0) Underwent robot-assisted radical prostatectomy (RARP) Age ≥ 18 years Complete clinical data including preoperative PSA, Gleason score, pathological T stage, and surgical margin status At least one postoperative PSA measurement available to determine biochemical recurrence status Signed informed consent for surgery and data use (or ethics committee waiver of consent for retrospective analysis) Exclusion Criteria: * Received neoadjuvant endocrine therapy, radiotherapy, or chemotherapy prior to surgery Concurrent active malignancy other than non-melanoma skin cancer Preoperative evidence of lymph node metastasis (N+), distant metastasis (M1), or clinical stage T3-T4 Missing core predictors (e.g., preoperative PSA, Gleason score, pathological T stage) or insufficient postoperative PSA data to determine BCR status Received adjuvant radiotherapy or adjuvant endocrine therapy before biochemical recurrence was determined Severe cardiac, hepatic, or renal dysfunction, or life expectancy \< 1 year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biochemical recurrence are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biochemical recurrence Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.